Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor
Clinical trial NCT00633295 · COMPLETED
Trial details
- NCT number
- NCT00633295
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2008-06-01
- Primary completion
- 2010-05-01
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.